Insulin prices have skyrocketed in recent years, working a hardship on the growing number of diabetics in the US. Progressive ...

But, that will soon be changing, due to biosimilars. As a result of the regulatory changes that occurred in March 2020, the first potential insulin biosimilar is on the horizon. Mylan and Biocon ...

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.

What led to the muted performance in the generics business? Generics revenue was Rs 624 crore, a decline of 8% YoY, ...

Dan Dischner; Vice President - Corporate Communications; Amphastar Pharmaceuticals Inc. William Peters; Chief Financial Officer, Executive Vice President - Finance, ...

Since the start of 2024, Wockhardt’s stock price has almost tripled to Rs 1,233.85 per share as on November 8.

Q3 2024 Earnings Call Transcript November 6, 2024Amphastar Pharmaceuticals, Inc. misses on earnings expectations.

Report Ocean, a leading strategic consulting and market research firm, in its recent study, estimated India Prefilled Syringes Market size by value at USD 1.13 billion in 2023. During the forecast ...

Amphastar Pharmaceuticals Inc (AMPH) reports a 6% revenue increase, driven by record Primatene Mist sales, despite facing competitive and logistical hurdles.

especially in self-administration of medications like insulin, vaccines, and biologics. The demand for syringe filling machines is further fueled by the global growth in chronic diseases, as well as ...

The drug is used to treat type 2 diabetes and obesity and it works by mimicking the effects of the body’s natural hormone, ...